Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
Heidelberg Pharma AG announced today that its licensing partner Telix Pharmaceuticals Limited, Melbourne, Australia, (Telix) presented positive top-line data on its pivotal ZIRCON Phase III study with the imaging agent TLX250-CDx, reporting that the study has meet all of its primary and secondary endpoints.